Cannabis firm InMed becomes migraine biotech Mentari in merger backed by $490M
What's the deal? InMed PharmaceuticalsDealroom has a profile for this one. Try Dealroom → has completed its merger with privately held Mentari TherapeuticsDealroom has a profile for this one. Try Dealroom →, converting the Nasdaq-listed company into a vehicle for Mentari's migraine-prevention pipeline. The combined company takes the Mentari name and is expected to begin trading as MTRI on November 9, 2026. Terms were not disclosed.
Why now? The closing arrives alongside roughly $490 million in private financings that Mentari completed just before the merger. That package includes the conversion of $50 million in previously issued convertible notes, plus accrued interest.
What's the endgame? Mentari, based in Waltham, Massachusetts, is developing therapies for migraine, a condition it says affects more than 1 billion people globally. Its lead programs are MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both PACAP and CGRP. The financing should fund development into 2029 and through Phase 2a readouts for the two programs.
What changes? Ahead of closing, the company redomesticated from British Columbia to Nevada and effected a 1-for-10 reverse stock split. Shareholders of record as of November 5 received one non-transferable contingent value right per share.
What could go wrong? Mentari's candidates target a pathway distinct from established CGRP migraine drugs, but they remain early-stage and unproven. The key test will be whether trials show benefit beyond existing options.
The signal: The large funding makes this a well-capitalized public-market launch for a clinical-stage biotech, bypassing a traditional IPO through a reverse merger. It also marks InMed's pivot away from cannabis-focused drug development into a new therapeutic area.
Read more: prnewswire.com
Image credit: Generated with Gemini
